# Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

> **NCT05061017** · PHASE2 · COMPLETED · sponsor: **Diwakar Davar** · enrollment: 13 (actual)

## Conditions studied

- NSCLC
- Metastatic Colorectal Carcinoma
- Refractory Melanoma

## Interventions

- **DRUG:** Pixatimod
- **DRUG:** Nivolumab
- **DRUG:** Cyclophosphamide (low dose)

## Key facts

- **NCT ID:** NCT05061017
- **Lead sponsor:** Diwakar Davar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-09
- **Primary completion:** 2024-02-05
- **Final completion:** 2024-03-18
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061017, "Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05061017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*